Edmond DE Rothschild Holding S.A. Sells 224 Shares of Agilent Technologies, Inc. (NYSE:A)

Edmond DE Rothschild Holding S.A. lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 0.6% during the 4th quarter, Holdings Channel reports. The firm owned 36,902 shares of the medical research company’s stock after selling 224 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Agilent Technologies were worth $4,957,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. CKW Financial Group lifted its stake in Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Global X Japan Co. Ltd. lifted its position in shares of Agilent Technologies by 161.1% in the fourth quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after buying an additional 116 shares in the last quarter. Lee Danner & Bass Inc. bought a new position in Agilent Technologies during the fourth quarter valued at approximately $29,000. Hanson & Doremus Investment Management grew its holdings in Agilent Technologies by 66.5% during the 4th quarter. Hanson & Doremus Investment Management now owns 263 shares of the medical research company’s stock valued at $35,000 after buying an additional 105 shares in the last quarter. Finally, OFI Invest Asset Management bought a new stake in Agilent Technologies in the 4th quarter worth approximately $37,000.

Insiders Place Their Bets

In other news, VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the transaction, the chief executive officer now directly owns 39,652 shares in the company, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on A shares. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Citigroup boosted their target price on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Robert W. Baird decreased their target price on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Bank of America dropped their price target on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, Wells Fargo & Company decreased their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Agilent Technologies currently has an average rating of “Moderate Buy” and a consensus target price of $150.83.

Agilent Technologies Stock Performance

A stock opened at $116.99 on Tuesday. Agilent Technologies, Inc. has a twelve month low of $113.76 and a twelve month high of $155.35. The firm has a market cap of $33.35 billion, a price-to-earnings ratio of 26.89, a PEG ratio of 3.27 and a beta of 1.11. The business’s fifty day simple moving average is $133.68 and its two-hundred day simple moving average is $136.49. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. The company had revenue of $1.68 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Analysts predict that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.85%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.76%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.